Mycobacterium tuberculosis growth at the cavity surface:: a microenvironment with failed immunity

被引:279
作者
Kaplan, G
Post, FA
Moreira, AL
Wainwright, H
Kreiswirth, BN
Tanverdi, M
Mathema, B
Ramaswamy, SV
Walther, G
Steyn, LM
Barry, CE
Bekker, LG
机构
[1] Publ Hlth Res Inst, TB Ctr, Newark, NJ 07103 USA
[2] Lab Mycobacterial Immun & Pathogenesis, Newark, NJ USA
[3] Univ Cape Town, Infect Dis Unit, ZA-7925 Cape Town, South Africa
[4] Univ Cape Town, Dept Thorac Surg, ZA-7925 Cape Town, South Africa
[5] Univ Cape Town, Dept Clin Lab Sci, ZA-7925 Cape Town, South Africa
[6] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[7] Univ Istanbul, Cerrahpasa Tip Fak, Istanbul, Turkey
[8] NYU, Sch Med, Dept Pathol, New York, NY USA
[9] NIAID, TB Res Sect, NIH, Rockville, MD USA
关键词
D O I
10.1128/IAI.71.12.7099-7108.2003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Protective immunity against pulmonary tuberculosis (TB) is characterized by the formation in the lungs of granulomas consisting of macrophages and activated T cells producing tumor necrosis factor alpha and gamma interferon, both required for the activation of the phagocytes. In 90% of immunocompetent humans, this response controls the infection. To understand why immunity fails in the other 10%, we studied the lungs of six patients who underwent surgery for incurable TB. Histologic examination of different lung lesions revealed heterogeneous morphology and distribution of acid-fast bacilli; only at the surface of cavities, i.e., in granulomas with a patent connection to the airways, were there numerous bacilli. The mutation profile of the isolates suggested that a single founder strain of Mycobacterium tuberculosis may undergo genetic changes during treatment, leading to acquisition of additional drug resistance independently in discrete physical locales. Additional drug resistance was preferentially observed at the cavity surface. Cytokine gene expression revealed that failure to control the bacilli was not associated with a generalized suppression of cellular immunity, since cytokine mRNA was up regulated in all lesions tested. Rather, a selective absence of CD4(+) and CD8(+) T cells was noted at the luminal surface of the cavity, preventing direct T-cell-macrophage interactions at this site, probably allowing luminal phagocytes to remain permissive for bacillary growth. In contrast, in the perinecrotic zone of the granulomas, the two cell types colocalized and bacillary numbers were substantially lower, suggesting that in this microenvironment an efficient bacteriostatic or bactericidal phagocyte population was generated.
引用
收藏
页码:7099 / 7108
页数:10
相关论文
共 34 条
[1]  
ANDERSON P, 1990, J IMMUNOL, V144, P574
[2]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[3]  
Bean AGD, 1999, J IMMUNOL, V162, P3504
[4]   TUBERCULOSIS - COMMENTARY ON A REEMERGENT KILLER [J].
BLOOM, BR ;
MURRAY, CJL .
SCIENCE, 1992, 257 (5073) :1055-1064
[5]   KILLING OF VIRULENT MYCOBACTERIUM-TUBERCULOSIS BY REACTIVE NITROGEN INTERMEDIATES PRODUCED BY ACTIVATED MURINE MACROPHAGES [J].
CHAN, J ;
XING, Y ;
MAGLIOZZO, RS ;
BLOOM, BR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (04) :1111-1122
[6]   Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases [J].
Chang, JC ;
Wysocki, A ;
TchouWong, KM ;
Moskowitz, N ;
Zhang, YH ;
Rom, WN .
THORAX, 1996, 51 (03) :306-311
[7]   Local immune responses correlate with presentation and outcome in tuberculosis [J].
Condos, R ;
Rom, WN ;
Liu, YM ;
Schluger, NW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (03) :729-735
[8]   THE PROTECTIVE IMMUNE-RESPONSE TO MYCOBACTERIUM-TUBERCULOSIS [J].
COOPER, AM ;
FLYNN, JL .
CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (04) :512-516
[9]   AN OUTBREAK OF TUBERCULOSIS WITH ACCELERATED PROGRESSION AMONG PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - AN ANALYSIS USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS [J].
DALEY, CL ;
SMALL, PM ;
SCHECTER, GF ;
SCHOOLNIK, GK ;
MCADAM, RA ;
JACOBS, WR ;
HOPEWELL, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (04) :231-235
[10]  
Dieli F, 2000, EUR J IMMUNOL, V30, P1512, DOI 10.1002/(SICI)1521-4141(200005)30:5<1512::AID-IMMU1512>3.0.CO